News

Actemra/RoActemra has potential to change how GCA is treated.

The drug is the first and only fully-human antagonist showing sustained skin clearance rates at 5 years.

The higher the dose the patient is exposed to, the greater the risk.

This study was the first to use an objective measure to link severity of psoriasis and risk of death.

The live varicella-zoster vaccine may be effective in patients with RA who are starting treatment with tofacitinib.

The study showed positive results in a difficult-to-treat patient population.

A different course, symptoms, and perceptions often results in different coping strategies and maybe even destructive behaviors.

Joint swelling has the best concordance with ultrasound diagnosis. Joint symptoms may be a better clinical indicator than tenderness evaluation.

An ICER analysis and expert commentary on anabolics’ benefits and costs offer some opposing views, and some consensus.

Tumor necrosis factor inhibitors and high-dose corticosteroids were the culprits.

Patients demonstrated improved disease response in 2 clinical trials.

They offer insight into patients’ true health status and ought to be at the forefront of healthcare decision making.

The latest recommendations emphasize providing key information about the disease and its treatment.

In a letter to the company, the FDA cited safety and dosage concerns as major factors in their decision.

Used with or separate from traditional measures, this tool can obtain a fast assessment of remission.

Elevations were related to disease progression in patients who had medial knee osteoarthritis, but not gout.

Study findings highlight the need for physicians to heed the symptoms of testosterone deficiency.

The new janus kinase 1 inhibitor used in combination with MTX produced rapid improvement in symptoms.

With clinical overlap, study findings suggest vigilance and an active search for underlying inflammatory disorders.

EULAR 2017: Romosozumab reduces the risk of clinical vertebral fractures in postmenopausal women with osteoporosis by as much as five times.

Tocilizumab may be associated with increasing LDL cholesterol in rheumatoid arthritis, but a new study shows that it is not associated with increased cardiovascular risk.

The drug helped patients achieve clinical remission, low disease activity.

The severity of long-term chronic pain that impedes daily life seems to be associated with higher mortality, researchers report.

Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.

A quick summary of the 2012 American College of Rheumatology guidelines for the management of gout.

The nuances of word choice in a doctor’s office may hold greater meaning than you think.

This study is among the first to show that aggressive treatment of early rheumatoid arthritis with biologic DMARDs benefits high-risk patients.

Tocilizumab in its subcutaneous form is the first-ever drug designated for giant cell arteritis which affects 230,000 people in the U.S

Systemic sclerosis. Its rarity could lead to delays in diagnosis which, according to a review, may not be fully understood by inexperienced physicians.

This is the first FDA-approved therapy specific to this form of vasculitis.